tradingkey.logo

Twist Bioscience Corp

TWST

34.070USD

-0.970-2.77%
Horário de mercado ETCotações atrasadas em 15 min
2.04BValor de mercado
PerdaP/L TTM

Twist Bioscience Corp

34.070

-0.970-2.77%
Mais detalhes de Twist Bioscience Corp Empresa
Twist Bioscience Corporation is a synthetic biology and genomics company that has developed a deoxyribonucleic acid (DNA) synthesis platform to industrialize the engineering of biology. The Company's platform's core is a proprietary technology that specializes in manufacturing synthetic DNA by writing DNA on a silicon chip. It has applied its technology to manufacture a range of synthetic DNA-based products, including synthetic genes, tools for next generation sequencing (NGS) sample preparation, and antibody libraries for drug discovery and development, all designed to enable its customers to conduct research. Its gene products include multiplexed gene fragments, express genes, clonal genes and gene fragments. The Company also manufactures synthetic ribonucleic acid (RNA) as well as antibody proteins. The Company's synthetic DNA tools are used in fields, such as medicine, agriculture, industrial chemicals and defense. It has minority ownership in Atlas Data Storage, Inc.
Informações da empresa
Código da empresaTWST
Nome da EmpresaTwist Bioscience Corp
Data de listagemOct 31, 2018
Fundado em2013
CEODr. Emily M. Leproust, Ph.D.
Número de funcionários923
Tipo de títulosOrdinary Share
Fim do ano fiscalOct 31
Endereço681 Gateway Blvd.
CidadeSOUTH SAN FRANCISCO
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal94080
Telefone18007190671
Sitehttps://www.twistbioscience.com/
Código da empresaTWST
Data de listagemOct 31, 2018
Fundado em2013
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Emily M. Leproust, Ph.D.
Dr. Emily M. Leproust, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
343.35K
-0.63%
Mr. Patrick John Finn, Ph.D.
Mr. Patrick John Finn, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
116.05K
-17.54%
Mr. Keith L. Crandell
Mr. Keith L. Crandell
Independent Director
Independent Director
92.71K
+5.07%
Mr. Dennis Cho
Mr. Dennis Cho
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
50.48K
-0.51%
Ms. Paula Green
Ms. Paula Green
Senior Vice President - Human Resources
Senior Vice President - Human Resources
47.51K
-1.76%
Mr. Nelson C. Chan
Mr. Nelson C. Chan
Independent Director
Independent Director
22.25K
+25.16%
Dr. Melissa A. Starovasnik, Ph.D.
Dr. Melissa A. Starovasnik, Ph.D.
Independent Director
Independent Director
15.81K
+39.44%
Mr. Jan Johannessen
Mr. Jan Johannessen
Independent Director
Independent Director
12.60K
+55.04%
Mr. Adam Laponis
Mr. Adam Laponis
Chief Financial Officer
Chief Financial Officer
10.70K
-8.04%
Mr. Robert Werner
Mr. Robert Werner
Chief Accounting Officer, Vice President
Chief Accounting Officer, Vice President
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Emily M. Leproust, Ph.D.
Dr. Emily M. Leproust, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
343.35K
-0.63%
Mr. Patrick John Finn, Ph.D.
Mr. Patrick John Finn, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
116.05K
-17.54%
Mr. Keith L. Crandell
Mr. Keith L. Crandell
Independent Director
Independent Director
92.71K
+5.07%
Mr. Dennis Cho
Mr. Dennis Cho
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
50.48K
-0.51%
Ms. Paula Green
Ms. Paula Green
Senior Vice President - Human Resources
Senior Vice President - Human Resources
47.51K
-1.76%
Mr. Nelson C. Chan
Mr. Nelson C. Chan
Independent Director
Independent Director
22.25K
+25.16%
Detalhamento da receita
Moeda: USDAtualizado em: dom, 6 de abr
Moeda: USDAtualizado em: dom, 6 de abr
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2021
FY2020
FY2019
Por EmpresaUSD
Nome
Receita
Proporção
NGS tools
48.64M
54.83%
Synthetic genes
26.48M
29.85%
Antibody discovery
5.70M
6.42%
Oligo pools
5.09M
5.74%
DNA and Biopharma libraries
2.79M
3.15%
DNA libraries
2.79M
3.15%
Por RegiãoUSD
Nome
Receita
Proporção
Americas
53.71M
60.54%
EMEA
28.30M
31.91%
APAC
6.70M
7.55%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
NGS tools
48.64M
54.83%
Synthetic genes
26.48M
29.85%
Antibody discovery
5.70M
6.42%
Oligo pools
5.09M
5.74%
DNA and Biopharma libraries
2.79M
3.15%
DNA libraries
2.79M
3.15%
Distribuição de ações
Atualizado em: ter, 20 de mai
Atualizado em: ter, 20 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
ARK Investment Management LLC
10.42%
The Vanguard Group, Inc.
9.77%
Artisan Partners Limited Partnership
9.77%
BlackRock Institutional Trust Company, N.A.
7.73%
William Blair Investment Management, LLC
6.35%
Other
55.96%
Investidores
Investidores
Proporção
ARK Investment Management LLC
10.42%
The Vanguard Group, Inc.
9.77%
Artisan Partners Limited Partnership
9.77%
BlackRock Institutional Trust Company, N.A.
7.73%
William Blair Investment Management, LLC
6.35%
Other
55.96%
Tipos de investidores
Investidores
Proporção
Investment Advisor
51.92%
Investment Advisor/Hedge Fund
49.22%
Hedge Fund
8.42%
Research Firm
3.10%
Individual Investor
1.98%
Pension Fund
1.42%
Bank and Trust
0.41%
Sovereign Wealth Fund
0.27%
Family Office
0.24%
Participação acionária institucional
Atualizado em: ter, 4 de mar
Atualizado em: ter, 4 de mar
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q1
565
67.44M
112.56%
-7.04M
2024Q4
578
67.47M
113.11%
-8.03M
2024Q3
588
67.80M
115.74%
-8.48M
2024Q2
579
66.59M
114.39%
-10.53M
2024Q1
565
68.18M
117.94%
-8.61M
2023Q4
559
67.81M
117.39%
-11.70M
2023Q3
560
68.09M
118.66%
-11.36M
2023Q2
577
69.42M
121.49%
-5.07M
2023Q1
593
64.77M
113.93%
-4.20M
2022Q4
610
60.52M
106.86%
-2.15M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
ARK Investment Management LLC
6.38M
10.7%
+786.30K
+14.05%
Feb 28, 2025
The Vanguard Group, Inc.
5.79M
9.71%
+189.79K
+3.39%
Dec 31, 2024
Artisan Partners Limited Partnership
5.89M
9.88%
-125.19K
-2.08%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
4.62M
7.75%
+119.93K
+2.66%
Dec 31, 2024
William Blair Investment Management, LLC
2.95M
4.95%
-527.57K
-15.17%
Dec 31, 2024
Invesco Advisers, Inc.
3.53M
5.92%
+25.56K
+0.73%
Dec 31, 2024
State Street Global Advisors (US)
2.54M
4.26%
-623.36K
-19.68%
Dec 31, 2024
Nikko Asset Management Co., Ltd.
2.61M
4.38%
-248.70K
-8.69%
Dec 31, 2024
Thrivent Asset Management, LLC
1.51M
2.52%
+532.04K
+54.64%
Dec 31, 2024
Ver Mais
ETFs Relacionados
Atualizado em: sex, 6 de jun
Atualizado em: sex, 6 de jun
Nome
Proporção
ARK Genomic Revolution ETF
6.34%
iShares Genomics Immunology and Healthcare ETF
2.62%
ARK Innovation ETF
2.1%
Global X Genomics & Biotechnology ETF
2.01%
WisdomTree BioRevolution Fund
1.82%
Franklin Genomic Advancements ETF
1.65%
ROBO Global Healthcare Technology & Innovation ETF
1.15%
BNY Mellon Innovators ETF
1.13%
Putnam Sustainable Future ETF
0.92%
First Trust Nasdaq Lux Digi Health Solutions ETF
0.85%
Ver Mais
ARK Genomic Revolution ETF
Proporção6.34%
iShares Genomics Immunology and Healthcare ETF
Proporção2.62%
ARK Innovation ETF
Proporção2.1%
Global X Genomics & Biotechnology ETF
Proporção2.01%
WisdomTree BioRevolution Fund
Proporção1.82%
Franklin Genomic Advancements ETF
Proporção1.65%
ROBO Global Healthcare Technology & Innovation ETF
Proporção1.15%
BNY Mellon Innovators ETF
Proporção1.13%
Putnam Sustainable Future ETF
Proporção0.92%
First Trust Nasdaq Lux Digi Health Solutions ETF
Proporção0.85%
Dividendo
Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
KeyAI